论文部分内容阅读
Sclerostin is a negative regulator of bone formation.Previous studies demonstrated that treatment with a sclerostin monoclonal antibody (Sc(1)-Ab) results in significantly increased bone formation,bone mass and strength in rat closed fracture model (1-2).However,the effects of Scl-Ab on healing of open fracture model have not yet been reported in rats.The objective of our project is to investigate the effects of systemic administration of Scl-Ab on fracture repair in rat femur open fracture,a more challenging clinical situations compare with closed fracture healing.